Log in

LON:PRTCPureTech Health Share Price, Forecast & News

GBX 278
+2.50 (+0.91 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
268.65
Now: GBX 278
295.33
50-Day Range
225
MA: GBX 260.08
293.50
52-Week Range
2.11
Now: GBX 278
339.36
Volume562,032 shs
Average Volume71,917 shs
Market Capitalization£793.72 million
P/E Ratio1.93
Dividend YieldN/A
BetaN/A
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia. In addition, the company is developing drug delivery platform for oral administration of proteins, peptides, and other difficult-to-deliver payloads; products to generate new human hair follicles and hair; drug delivery platform for drugs that treat inflammation and associated disorders; platform to address immunosenescence; novel targeted immunotherapies for cancer; monoclonal antibodies for immuno-suppressive gamma delta T cells in pancreatic and colorectal cancers, and other solid tumors; novel approaches to enhance delivery and distribution of therapeutics; and digital health technologies, as well as engages in enhancing health through food through the creation of nutrition technology. Further, it is developing a platform and products that take in physiological data from sensors and correlates that data with musical data components; voice-based tools for passive assessment and tracking of patient health; commensal organism-based products for enhancing human health; and technology platform to identify experts in healthcare and other research-based disciplines, as well as engages in identifying healthcare expert networks and reviewing their conversations and content on social media. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Read More
PureTech Health logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.8Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.31 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-617-4822333

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£9.81 million
Cash FlowGBX 57.73 per share
Book ValueGBX 234.10 per share

Profitability

Miscellaneous

Employees300
Market Cap£793.72 million
Next Earnings DateN/A
OptionableNot Optionable

Receive PRTC News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTC and its competitors with MarketBeat's FREE daily newsletter.

PureTech Health (LON:PRTC) Frequently Asked Questions

How has PureTech Health's stock been impacted by COVID-19 (Coronavirus)?

PureTech Health's stock was trading at GBX 274 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PRTC stock has increased by 1.5% and is now trading at GBX 278. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of PureTech Health?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PureTech Health in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for PureTech Health.

What price target have analysts set for PRTC?

3 brokers have issued 12 month price targets for PureTech Health's stock. Their forecasts range from GBX 450 to GBX 480. On average, they anticipate PureTech Health's stock price to reach GBX 470 in the next twelve months. This suggests a possible upside of 69.1% from the stock's current price. View analysts' price targets for PureTech Health.

Has PureTech Health been receiving favorable news coverage?

News headlines about PRTC stock have been trending neutral on Saturday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. PureTech Health earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about PureTech Health.

Who are some of PureTech Health's key competitors?

What other stocks do shareholders of PureTech Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PureTech Health investors own include Nemaska Lithium (NMX), Yamana Gold (YRI), Asanko Gold (AKG), Arotech (ARTX), Boeing (BA), Baozun (BZUN), Chaarat Gold (CGH), Eldorado Gold (ELD), CarMax (KMX) and Knowles (KN).

Who are PureTech Health's key executives?

PureTech Health's management team includes the following people:
  • Ms. Daphne Zohar, Founder, CEO & Exec. Director (Age 47)
  • Dr. Bennett M. Shapiro, Co-Founder & Non-Exec. Director (Age 78)
  • Dr. Robert S. Langer Jr., Co-Founder, Non-Exec. Director & Member of Scientific Advisory Board (Age 69)
  • Mr. Stephen M. Muniz J.D., COO, Exec. VP of Legal & Operations, Sec. and Exec. Director (Age 48)
  • Dr. Bharatt M. Chowrira, Pres and Chief of Bus. & Strategy (Age 53)

What is PureTech Health's stock symbol?

PureTech Health trades on the London Stock Exchange (LON) under the ticker symbol "PRTC."

How do I buy shares of PureTech Health?

Shares of PRTC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is PureTech Health's stock price today?

One share of PRTC stock can currently be purchased for approximately GBX 278.

How big of a company is PureTech Health?

PureTech Health has a market capitalization of £793.72 million and generates £9.81 million in revenue each year. PureTech Health employs 300 workers across the globe.

What is PureTech Health's official website?

The official website for PureTech Health is puretechhealth.com.

How can I contact PureTech Health?

PureTech Health's mailing address is 501 Boylston St Ste 6102, BOSTON, MA 02116-3769, United States. The company can be reached via phone at +1-617-4822333.

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.